Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 166Polycystic Ovary Syndrome 23Neoplasm Metastasis 10Osteoporosis 7Neoplasms 6Infertility 6Endometrial Neoplasms 5Carcinoma, Intraductal, Noninfiltrating 5Ovarian Neoplasms 4Breast Carcinoma In Situ 4Arthralgia 4Recurrence 3Hereditary Sensory and Autonomic Neuropathies 3Carcinoma, Ductal, Breast 3Breast Neoplasms, Male 3Breast Cancer Metastatic 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 2Pain 2Leiomyoma 2Fallopian Tube Neoplasms 2Estrogen Receptor-positive Breast Cancer 2Carcinoma, Lobular 2Bone Diseases, Metabolic 2Uterine Neoplasms 1Patient Acceptance of Health Care 1Ovarian Cysts 1Osteitis Deformans 1Obesity 1Neoplastic Cells, Circulating 1

Interventions

Letrozole 2palbociclib 1Fulvestrant 1Diet, Ketogenic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Estrogen Receptor-positive Breast Cancer × Letrozole × Clear all
NCT03962647 2026-04-30

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Completed
31 enrolled
Breast

Estrogen Receptor-positive Breast Cancer

NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡